Magnetoencephalography as a Biomarker for HIV-Associated Neurocognitive Disorder

脑磁图作为 HIV 相关神经认知障碍的生物标志物

• 批准号: 8469618
• 负责人: JAMES T. BECKER
• 金额: $ 22.02万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-21 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8469618
• 关键词: AIDS Dementia Complex; AIDS neuropathy; Activities of Daily Living; Address; Affect; Area; Automobile Driving; Biological; Biological Markers; Brain; Caring; Cerebrovascular Circulation; Chronic; Clinical; Cognition; Cognition Disorders; Cognitive; Cognitive deficits; Country; Data; Dementia; Development; Differential Diagnosis; Disease; Emerging Technologies; Employment; Enrollment; Epilepsy; Exploratory/Developmental Grant; Eye; Functional Magnetic Resonance Imaging; Functional disorder; Funding; Goals; HIV; Image; Impaired cognition; Individual; Life; Longitudinal Studies; MRI Scans; Magnetic Resonance Imaging; Magnetoencephalography; Measures; Medical; Methods; Modality; Modeling; Morphologic artifacts; Movement; Neurocognitive; Neurons; Neuropsychological Tests; Outcome; Participant; Pathology; Patients; Performance; Physiologic pulse; Pilot Projects; Population; Positron-Emission Tomography; Price; Publishing; Recovery; Relative (related person); Research; Research Project Grants; Resolution; Rest; Scanning; Screening procedure; Secondary to; Series; Signal Transduction; Signs and Symptoms; Spin Labels; Study Subject; Synapses; Techniques; Technology; Testing; Therapeutic; Woman; base; blood oxygen level dependent; design; imaging modality; magnetic field; medication compliance; meetings; memory recognition; neurobehavioral; neuroimaging; neuropsychological; novel; research clinical testing; response; tool; volunteer; white matter damage

DESCRIPTION (provided by applicant): HIV disease is becoming more of a chronic condition in countries with good access to medical care. In the area of NeuroAIDS there is no acknowledged, useful biomarker for the cognitive disorder associated with HIV disease (i.e., HIV-Associated Neurocognitive Disorder (HAND)), independent of the cognitive tests. Magnetic resonance imaging and positron emission tomography have been tried, but have yet to fulfill their promise {Price, 2007 #6509}. One emerging technology that has only recently been applied to HIV Disease - by our research team - is magnetoencephalography (MEG). MEG is a non-invasive technique for measuring neuronal activity by recording the magnetic fields induced by synchronized neuronal currents. MEG has the highest spatial and temporal resolution of any current neuroimaging technology, and is used most commonly in the clinical evaluation of patients with seizure disorders, and by cognitive neuroscientists to investigate electrophysiological responses of the CNS. Unlike techniques such as functional MRI, MEG does not rely on the blood-oxygen level dependent response in order to generate responses. Thus, it will be very important to determine whether MEG can identify abnormal brain function in HIV Disease - especially when cognitive dysfunction is mild and not yet affecting activities of daily living. Our team has demonstrated that we can differentiate infected from uninfected study subjects, that there may be an independent MEG-derived variable that is sensitive to cognitive dysfunction, and that MEG signals are stable over a 6-month period. The preliminary research was conducted in the context of an R03-funded study, so the overall goal of this new R21 research project is to obtain the necessary additional data from 30 infected individuals (and 10 controls) to finalize the design for a larger, longitudinal study. These data will allow us to begi to characterize the neurocognitive outcomes of HIV Disease using a highly sensitive electrophysiological tool. PUBLIC HEALTH RELEVANCE: HIV infected patients can still have abnormalities in cognition ranging from the more common mild deficits, to the less common, but more devastating dementia. What is missing in the field of NeuroAIDS is a tool that will provide information about the biological state of the brain that is related to the cognitive impairment. We propose to study Magnetoencephalography (MEG) as a potential biomarker. In this project, we will find out whether it is feasible to use MEG in patients with NeuroAIDS, and we will decide exactly how to design a larger, longitudinal study.

描述（由申请人提供）：在医疗条件良好的国家，艾滋病毒疾病正在成为一种慢性疾病。在NeuroAIDS领域，对于与HIV疾病相关的认知障碍没有公认的有用的生物标志物（即，HIV相关的神经认知障碍（HAND）），独立于认知测试。已经尝试了磁共振成像和正电子发射断层扫描，但尚未实现其承诺{Price，2007 #6509}。我们的研究小组最近才将一项新兴技术应用于艾滋病，这就是脑磁图（MEG）。脑磁图（MEG）是一种非侵入性的神经元活动测量技术，通过记录同步神经元电流所产生的磁场来测量。脑磁图具有最高的空间和时间分辨率的任何当前的神经成像技术，最常用于临床评估癫痫患者，并由认知神经科学家研究的电生理反应的中枢神经系统。与功能性MRI等技术不同，MEG不依赖于血氧水平依赖性反应来产生反应。因此，确定MEG是否可以识别HIV疾病中的异常脑功能将非常重要-特别是当认知功能障碍是轻度的并且尚未影响日常生活活动时。 我们的团队已经证明，我们可以区分感染与未感染的研究对象，可能存在一个独立的MEG衍生变量，对认知功能障碍敏感，并且MEG信号在6个月内保持稳定。初步研究是在R 03资助的研究背景下进行的，因此这项新的R21研究项目的总体目标是从30名感染者（和10名对照）中获得必要的额外数据，以最终确定更大的纵向研究的设计。这些数据将使我们能够开始使用高度敏感的电生理工具来描述HIV疾病的神经认知结果。 公共卫生关系：艾滋病毒感染者仍然可以有认知异常，从更常见的轻度缺陷，到不太常见但更具破坏性的痴呆症。NeuroAIDS领域缺少的是一种工具，它将提供与认知障碍相关的大脑生物状态的信息。我们建议研究脑磁图（MEG）作为一个潜在的生物标志物。在这个项目中，我们将发现是否可以在NeuroAIDS患者中使用MEG，我们将决定如何设计一个更大的纵向研究。